‘The Group Room’ Radio Talk Show Celebrates Three Years on the Air

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 4
Volume 8
Issue 4

LOS ANGELES-“The Group Room,” a nationally syndicated cancer radio talk show, entered its third year on the air with new markets, accolades for its host Selma Schimmel, and a new book based on the show.

LOS ANGELES—“The Group Room,” a nationally syndicated cancer radio talk show, entered its third year on the air with new markets, accolades for its host Selma Schimmel, and a new book based on the show.

The recently signed new markets are in Alabama, Florida, Idaho, Pennsylvania, and Tennessee. The book is called Cancer Talk, and the honor for Ms. Schimmel is being named one of the “Heavy Hundred” by the radio industry publication Talkers Magazine. The “Heavy Hundred” represent the most important radio talk show hosts in America. Ms. Schimmel is a 16-year breast cancer survivor and founder of Vital Options, the national cancer support, advocacy, and communications organization.

“It is an honor to receive this recognition, especially when you consider that there are 4,500 talk shows nationwide,” Ms. Schimmel said. “I want to acknowledge Premiere Radio Networks and our founding sponsor, Bristol-Myers Squibb; corporate sponsors Ortho Biotech and Pharmacia & Upjohn; and the hundreds of local supporters and radio stations who make this show possible every week.”

The program airs live each Sunday from 4 to 6 pm Eastern Daylight Time in major markets and can also be heard live on the Internet at www.vitaloptions.org.

Cancer Talk, a book of hope and lessons in endurance culled from conversations on the radio show, was written by Ms. Schimmel and is due out this spring from Broadway Books, a division of Random House.

Recent Videos
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content